Schwann cell development, maturation and regeneration: a focus on classic and emerging intracellular signaling pathways

Luca Franco Castelnovo, Veronica Bonalume, Simona Melfi, Marinella Ballabio, Deborah Colleoni, Valerio Magnaghi
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy

How to cite this article: Castelnovo LF, Bonalume V, Melfi S, Ballabio M, Colleoni D, Magnaghi V (2017) Schwann cell development, maturation and regeneration: a focus on classic and emerging intracellular signaling pathways. Neural Regen Res 12(7):1013-1023.

Funding: Financial support by University of Milan, institutional funding "Piano di sostegno per la ricerca 2016 -Linea 2 Azione B", is gratefully acknowledged.

Abstract
The development, maturation and regeneration of Schwann cells (SCs), the main glial cells of the peripheral nervous system, require the coordinate and complementary interaction among several factors, signals and intracellular pathways. These regulatory molecules consist of integrins, neuroregulins, growth factors, hormones, neurotransmitters, as well as entire intracellular pathways including protein-kinase A, C, Akt, Erk/MAPK, Hippo, mTOR, etc. For instance, Hippo pathway is overall involved in proliferation, apoptosis, regeneration and organ size control, being crucial in cancer proliferation process. In SCs, Hippo is linked to merlin and YAP/TAZ signaling and it seems to respond to mechanico-physical challenges. Recently, among factors regulating SCs, also the signaling intermediates Src tyrosine kinase and focal adhesion kinase (FAK) proved relevant for SC fate, participating in the regulation of adhesion, motility, migration and in vitro myelination. In SCs, these factors Src and FAK are regulated by the neuroactive steroid allopregnanolone, thus corroborating the importance of this steroid in the control of SC maturation. In this review, we illustrate some old and novel signaling pathways modulating SC biology and functions during the different developmental, mature and regenerative states.

Key Words: myelin; neuroactive steroids; electromagnetic field; peripheral nervous system

Introduction
Schwann cells (SCs) are the main glial cells of the peripheral nervous system (PNS). Their main function is the formation of the myelin sheath, which electrically isolates axons, allowing salutary conduction of the action potential. Actually, their function is more complex, playing a fundamental role in different processes, from the development of the PNS (Feltri et al., 2016) to the post-injury nerve repair (Jessen and Mirsky, 2016). In this review, we first illustrate the different phases of SC development and differentiation, describing some of the different signals involved. Then, we discuss in detail some novel receptors and signaling pathways controlling SC biology and functionality during the different developmental, mature and regenerative states.

SCs from Development to Injury
SC development starts from neural crest cells, and leads to the formation of mature myelinating and non-myelinating SCs (Figure 1). The development process goes through different stages that require a dynamic control of SC morphology, with an accurate balance between proliferation and differentiation. These developmental stages include: neural crest cells, SC precursors, immature SCs, pro-myelinating SCs and mature myelinating and/or non-myelinating SCs (Monk et al., 2015). Neural crest cells (Figure 1A) delaminate from the dorsal region of the neural tube. They possess high proliferative and migratory capacity, originating a wide range of cell types, including the cardiac cells, the skeletal and connective components of the head, the melanocytes, as well as neurons and glial cells of the PNS. Initially, the neural crest induction from the ectoderm requires some signals, such as the bone morphogenetic protein (BMP), fibroblast growth factor (FGF) and the activation of the Wnt signaling pathway (Stuhlmiiller and García-Castro, 2012). Successively, other factors seem to be fundamental for the differentiation of neural crest cells into SC precursors, including the transcription factor Sox10 (Woodhoo and Sommer, 2008), the neuregulin-1 (NRG-1) system (Shah et al., 1994), and the histone deacetylases (HDAC) isoforms 1 and 2 (HDAC1, 2) (Jacob et al., 2014). However, the molecular machinery required for these initial stages of SC differentiation has not been completely elucidated.

Similarly to neural crest cells, SC precursors (Figure 1B) are proliferative and migratory, and rely on axonal signals for survival. A determinant of SC precursor development is the NRG-1/ErbB2/3 signaling system (Raphael and Talbot, 2011). Successively, SC precursors develop into immature SCs, with a mechanism involving the activation of Notch signaling (Woodhoo et al., 2009). These cells lose their migratory capacity. Differently from the previous stage, immature SCs are dependent on autocrine signaling for survival (Jessen and Mirsky, 2005).
Immature SCs (Figure 1C) are involved in the radial sorting process, during which axons separate based on their caliber. In rodents and humans, this physiologic process starts perinatally and continues during development, determining the morphologic aspect of the mature PNS, in which larger axons are myelinated (Feltri et al., 2016). During this phase, immature SCs undergo cytoskeletal remodelling, leading to the extension of filipodia and lamellipodia. These specialized structures enable SCs to surround axons of mixed calibers and to send cytoplasmic processes between axons, to progressively choose and segregate the larger axons at the periphery of the bundle (Feltri et al., 2016). Thus, immature SCs which enter in a 1:1 ratio with larger axons, and later proceed towards the pro-myelinating phenotype; SCs that contact small caliber axons, indeed, differentiate towards the non-myelinating phenotype (Figure 1D), leading to the formation of Remak bundles (Salzer, 2015; Feltri et al., 2016). Radial sorting is controlled by several factors, although the main determinants of this process are components of the extracellular matrix (e.g., laminin 211 and 411 or collagen XV), their specific receptors (e.g., integrins α6β1 and α7β1 or dystroglycan) (Monk et al., 2015) and the downstream intracellular-activated pathways, such as the Rho family kinases or merlin (see following paragraphs).

Hereafter, pro-myelinating SCs progress towards the myelinating phenotype (Figure 1D), in which mature myelinating SCs form the myelin sheath around large caliber axons. A master regulator of this process is NRG-1 type III (Taveggia, 2016), although other molecules are equally involved. For instance, important functions are played by receptor belonging to the G-protein coupled receptors (GPCRs) family, such as GPR126 (Monk et al., 2009), GPR44 (Trimarco et al., 2014) and the gamma-aminobutyric (GABA) type B (GABA-B) receptor (Procacci et al., 2012; Faroni et al., 2014). After the differentiation program, the myelinating and non-myelinating SCs may run into pathophysiological condition such as the nerve injury, thus re-changing their differentiation state. The repairing SC phenotype (Figure 1D) is sometimes mistaken with the pre-myelinating immature SC phenotype. However, the two phenotypes present different peculiar characteristics. Repairing SCs present a series of typical biomarkers, such as Olig1, Shh and artemin, all under the control of the transcription factor c-Jun. These proteins are lightly or not expressed in immature SCs (Jessen and Mirschky, 2016). After nerve injury, the activated SCs proliferate to form a SC column, the so-called band of Büngner, which facilitates the axonal regeneration and the general PNS regrowth. A lot of molecules were found to be involved in the nerve regeneration process, including adhesion proteins, extracellular matrix, and neurotrophic factors. Some of the novel signaling pathways controlling all these SCs stages are described below.

**Rac1, Cell Division Control Protein 42 (cdc42), FAK and Src**

Cdc42 and FAK are potent regulators of SC proliferation and survival, and they are basic to generate enough cells to engage with axons (Fernandez-Valle et al., 1998; McLean et al., 2004). During the embryonic stages, absence of FAK expression and activation causes a significant reduction in the number of SC precursors. Further experiments demonstrated no increase in SC apoptosis, confirming that the major process regulated by cdc42 and FAK in SCs was the positive modulation of cell proliferation (Grove et al., 2007).

Moreover, as mentioned above, some of the intracellular molecules involved in axonal sorting are the Rho family kinases, such as the small GTP binding protein Rac1 and the cdc42 protein. Other important factors are FAK, protein kinase A (PKA) and neurofibromin 2 (Nf2)/merlin, all downstream the control of β-integrin and laminin (Benninger et al., 2007; Grove et al., 2007; Pereira et al., 2009; Guo et al., 2013a, b). Rho GTPases are expressed by SCs (Terashima et al., 2001). *In vitro* experiments using dominant-negative and constitutively active forms of Rac1 and cdc42 indicated that these small GTPases, together with FAK, may be responsible for the growth factor mediated activation of SC motility (Cheng et al., 2000).
The interaction between integrin and laminin proteins located at the interface of SCs with the extracellular matrix (Figure 2A), causes FAK phosphorylation and in turn cdc42 activation (Schwartz and Shattil, 2000). Cdc42 then stimulates merlin phosphorylation through p21-activated kinase-dependent (PAK) activation (Thaxton et al., 2008). SCs with high levels of phosphorylated merlin were reported to assume a multipolar phenotype, which is necessary for the radial sorting process (Thaxton et al., 2011). In this light, the interaction of SCs with the extracellular matrix during the PNS development can activate this pathway, determining the SC multipolar morphology and radial sorting process. Later in SC development, at the myelination onset, a sort of negative feedback might control the phosphorylation cascade involving FAK, cdc42, PAK, and merlin (Figure 2B). In that case the non-phosphorylated merlin exerts a suppressor function, inhibiting cdc42-mediated activation of PAK (Kissil et al., 2003; Hirokawa et al., 2004; Okada et al., 2005).

Alteration of this intracellular cascade may change the entire axonal sorting process. Indeed, the ablation of FAK, as shown in vivo in mutant SCs, leads to the arrest of large-caliber axon sorting, likely based on the dramatic reduction in SC proliferation during the embryonic stages (Grove et al., 2007). Furthermore, ablation of either cdc42 or Rac1 impaired the radial sorting of axons, suggesting that cdc42 is required for SC proliferation while Rac1 is necessary to correct the SC extension and stabilization (Benninger et al., 2007).

The non-receptor-type tyrosine kinase Src is a key component of different signal transduction pathways that are involved in a wide range of cellular processes, including cell growth, migration, and differentiation. Formerly, Src was shown to be highly enriched in developing axonal tracts in the PNS, decreasing to lower levels during maturation (Bare et al., 1993). However, its expression is enhanced following peripheral nerve injury (Fu and Gordon, 1997). Consistently, SCs distal to the injury site were shown to express high levels of the active dephosphorylated form of Src (Zhao et al., 2003). It has been shown that Src can also modulate FAK. FAK phosphorylation at Tyr395 is an early event, leading to the exposure of a docking site for Src (Schaller et al., 1994). Under this conditions, Src can further phosphorylate FAK (Figure 2C), promoting its full activation (Calabri et al., 1995) that may occur via cdc42 and merlin signals.

Likely, FAK is required for proliferation, spreading and SC differentiation (Grove et al., 2007). However, in adult SCs FAK seems to be inactive, either for myelin maintenance or for re-myelination after nerve injury (Grove and Brophy, 2014). These findings suggest a primary role of FAK during SC development but not during SC maturation or regeneration. However, it should be underlined that in mature SCs, Src can be also modulated by other stimuli, such as neuroactive steroids (Melli et al., 2017). Indeed, it was demonstrated that Src is directly activated by allopregnanolone (ALLO) via a GABA-A dependent mechanism, can modulate Src and FAK. This activation promotes the myelination, thus representing a potential approach towards the regulation of SC maturation, likely in post-injury conditions (panel C). ALLO: Allopregnanolone; cdc42: cell division control protein 42; FAK: focal adhesion kinase; GABA-A: γ-aminobutyric acid-A; rac1: Ras-related C3 botulinum toxin substrate.

Figure 2 Scheme of some intracellular pathways involving FAK, cdc42, rac1, Src and merlin, in Schwann cell (SC) development, radial sorting, myelination and nerve repair.

Firstly, during the PNS development, the interaction of SCs with the extracellular matrix can phosphorylate FAK, activate cdc42, then phosphorylate merlin, determining the SC multipolar morphology and radial sorting process (panel A). Later, during the myelination onset, this phosphorylation cascade may be controlled by a sort of negative feedback, in which the non-phosphorylated merlin exerts a suppression of cdc42 and rac1, thus promoting myelination. The SC transition toward the bipolar morphology, thus, initiates the myelination process (panel B). In mature SCs, the neuroactive steroid ALLO, via a GABA-A dependent mechanism, can modulate Src and FAK. This activation promotes the myelination, thus representing a potential approach towards the regulation of SC maturation, likely in post-injury conditions (panel C). ALLO: Allopregnanolone; cdc42: cell division control protein 42; FAK: focal adhesion kinase; GABA-A: γ-aminobutyric acid-A; rac1: Ras-related C3 botulinum toxin substrate.
wards the regulation of SCs maturation and the development of novel therapies for the peripheral neuropathies.

**NF2/Merlin**

NF2 gene encodes the tumor suppressor protein neurofibromin, also named merlin, a cytoskeleton-associated protein belonging to the ezrin-radixin-moesin (ERM) family, which serves as tumor-suppressor protein in different cells. Mutations in the NF2 gene are associated with the autosomal dominant multiple syndrome called neurofibromatosis type 2 (Hadfield et al., 2010).

Merlin links the cell membrane to the cytoskeleton, regulating some intracellular signaling pathways, thus leading to cell disorganization when merlin is inactivated. Furthermore, merlin locates to the nucleus and inhibits E3 ubiquitin ligase CRL4CASC5 (Brodhun et al., 2017), thus suppressing the nuclear tumorigenesis (Li et al., 2014). Loss of merlin activates Rac1 and Ras, as well as PAK1, EGFR-Ras-ERK, PI3K-Akt, the mammalian target of rapamycin complex 1 (mTORC1), and Wnt pathways. However, the major effect downstream merlin in regulating growth is the Hippo pathway, a master regulator of proliferation, survival and migration in mammalian cells (Meng et al., 2016). Merlin was proved to suppress tumorigenesis by activating the Hippo pathway (Zhang et al., 2010). Intriguingly, CRL4CASC1 controls an oncogenic program of genes that includes the TEA domain family member (TEAD) target genes, thus suggesting that merlin regulates Hippo signaling by inhibiting CRL4CASC1 (Li and Giancotti, 2010). In any case, all these complex mechanisms are controversial and not completely elucidated, even in SCs.

For instance, during the first stages of myelination (Figure 2B), the activation of β1 integrin by the extracellular matrix on the SC surface, as well as the ErbB2 activation, at the SC-axon interface, can gradually decline the levels of phosphorylated merlin. This allows the SC transition toward a bipolar morphology, establishing a stable 1:1 association with axons that initiates the myelination process (Thaxton et al., 2011). Then, merlin stabilizes the bipolar morphology of SCs through inhibition of Rac1 (Thaxton et al., 2011).

Conversely, in Rac1 SC conditional knock-out (Rac1-CKO) mice, it was shown that the phosphorylation of PAK determines a decreased merlin phosphorylation (in agreement with cdc42 functions described above), but in this case the process induces the arrest of SC myelination (Guo et al., 2012). Moreover, it was also shown that, in the absence of Rac1, the non-phosphorylated form of merlin negatively regulates cAMP-mediated myelination. Accordingly, the NF2/merlin mutation in Rac1-CKO SC restored the cAMP levels, allowing myelin formation (Guo et al., 2012).

Overall, these findings, together with those described above, support a novel pathway in which Rac1 regulates SC myelination through NF2/merlin and cAMP signaling (Figure 2B).

Merlin is also a negative regulator of mTORC1. In NF2-related tumors, the functional loss of merlin activates the mTORC1 signaling. However, the mTOR inhibitor rapamycin limited but did not suppress tumorigenesis. Blocking mTORC1 signaling with rapamycin also resulted in elevated phosphorylated Akt levels (Giovannini et al., 2014). Considering the emerging importance of the mTOR signaling in SCs (described below), the interaction between merlin and mTOR pathway deserves deeper analysis.

Furthermore, a recent paper revealed a novel role for merlin and its effector Yes-associated protein (YAP; see below) in the control of SC plasticity and peripheral nerve repair after injury. It was shown that loss of merlin in repairing competent SCs determines a strong failure of axonal regeneration and SC capacity to re-myelinate correctly the large diameter axons (Mindos et al., 2017). Finally, it has been suggested that also some non-coding small RNAs or micro RNAs (miRNAs) may be modulated because of NF2 gene mutation. miRNAs are master regulators of gene expression, which are often deregulated in human tumorigenesis. Many miRNAs are changed in different types of tumours (Torres-Martin et al., 2013), suggesting their potential involvement also in neurofibromatosis type 2. Torres-Martin and colleagues demonstrated the deregulation of 174 miRNAs, including the upregulation of miR-10b, miR-206, miR-183, miR-133b, and the downregulation of miR-431, miR-221 and miR-493, in different forms of vestibular schwannoma with NF2 mutations (Torres-Martin et al., 2013). However, as single miRNAs are predicted to target hundreds of transcripts, the role played by miRNAs in SCs is rather complicated. For this reason we refer to other more focused reviews on the argument (Dugas and Notterpek, 2011; Svaren, 2014).

### YAP, Transcriptional Co-activator with PDZ-Binding Motif (TAZ), and the Hippo Pathway

YAP and TAZ are two transcriptional coactivators, active in the steps downstream the Hippo pathway (Dupont et al., 2011). They play important roles in organ growth, cell differentiation, proliferation and survival. YAP and TAZ shuttle from the cytoplasm into the nucleus (Zhao et al., 2008; Zhang et al., 2009), where they interact with some DNA-binding transcription factors, such as TEAD1, controlling the gene expression of the peripheral myelin protein of 22 kDa (PMP22) (Lopez-Anido et al., 2016). In the cytosol, YAP and TAZ are phosphorylated and inhibited by LATS1/2 kinases.

The nucleo-cytoplasmic shuttling of YAP and TAZ is critical for regulating cell proliferation during development, a phenomenon ensuring normal tissue growth and organ size (Piccolo et al., 2014). Hence, the nuclear translocation in differentiated adult cells is essential for cancer initiation and for solid tumor growth (Moroishi et al., 2015), making them a promising target for cancer therapies. YAP and TAZ are critical for immature SC development and myelin gene regulation. In particular, these transcriptional regulators are required for SC proliferation and axonal sorting; SCs require YAP and TAZ to enter S-phase and, without them, fail to generate sufficient SCs for axonal sorting (Grove et al., 2017).
YAP and TAZ are also required for SC differentiation, regulating the transcription of Krox20 (Grove et al., 2017), which is a well-known modulator of the myelination program in SCs (Topliko et al., 1994). However, it has been suggested that the capability of YAP and TAZ to initiate and maintain SC myelination may depend by different pathways (not strictly dependent by Krox20), such as the transcription factor Zeb2; this factor is positively regulated by YAP and TAZ and promotes SC differentiation by inhibiting some differentiation repressors (Quintes et al., 2016). YAP and TAZ can also activate the mTORC1 pathway to promote myelination (Kim et al., 2015). Moreover, YAP and TAZ are downstream different regulators of myelination, including NRG-1 type III, integrin α6β1, Gpr126 and Wnt (Quintes et al., 2016; Grove et al., 2017). Indeed, in myelinating SCs these coactivators are regulated by the extracellular matrix (Lopez-Anido et al., 2015; Poitelon et al., 2016). YAP and TAZ are two core factors in the Hippo pathway (Meng et al., 2016), integrating also biochemical and mechanical signals in the cells.

The Hippo pathway, indeed, may be modulated by mechanism-transduction in SCs (as described below) and these Hippo-mediated mechanisms are suggested to be involved in the omo-transformation of SCs and in the schwannoma pathogenesis (Colciago et al., 2015; Melﬁ et al., 2015).

HDACs are an important class of epigenetic modulators in SCs. HDACs are chromatin-remodelling proteins, capable of removing acetyl groups from histone tails, favouring chromatin condensation, and making it less accessible for transcription factors (Jacob et al., 2011). HDACs can also act at a non-epigenetic level, de-acetylating different targets, including some transcription factors (Glozak et al., 2005). HDAC proteins, and in particular the isoforms HDAC1 and HDAC2, were shown to play an important role during development (Jacob et al., 2014) and in postnatal SCs (Jacob et al., 2011).

During the establishment of the SC lineage from the neural crest, an important determinant of SC development is the expression of presence of high Sox10 levels. In these cells, HDAC1 and HDAC2 do not activate directly Sox10, but they induce the expression of transcription factor Pax3, which in turn maintains high Sox10 levels and promoting the expression of other important SC lineage markers, such as proteins P0 and Fabp7 (Jacob et al., 2014).

HDACs have important roles also in SC myelination and postnatal cell survival. Indeed, the double loss of function of HDAC1 and HDAC2 induced partial defects in axonal sorting, blocking myelination (Jacob et al., 2011). Differently from the neural crest cells, in mature SCs, HDACs bind the regulatory regions of Sox10, Krox20 and P0. However, only HDAC2 proved able to promote directly the myelination process, increasing the expression levels of some SC myelination markers, such as Sox10, Krox20, P0, as well as the myelin basic protein (MBP) and the myelin associated glycoprotein (MAG). In this regard, Sox10 plays a critical role by activating its own transcription, in turn increasing Krox20 expression, in synergy with HDAC2 (Jacob et al., 2011). Conversely, HDAC1 is a controller of SC survival during the first postnatal days, through a mechanism that involves the expression of β-catenin. The upregulation of β-catenin mediated by Wnt signaling induces the apoptosis in carcinoma cells (Bordonaro et al., 2007). Accordingly, the Wnt inhibition blocks the effect of HDAC1 knockout, confirming a role for this pathway in the HDAC1-mediated modulation of cell death during the early postnatal days (Jacob et al., 2011).

**GPR126 and GPR44**

GPR126 is a receptor belonging to the GPCR family, which proved necessary for myelination in zebrafish and mouse (Monk et al., 2009, 2011). From a mechanistic point of view, GPR126 was shown to act mainly by modulating intracellular cAMP levels, being able to couple both G-inhibitory (Gi) and G-stimulatory (Gs) proteins (Mogha et al., 2013). However, the Gs-mediated action seems to be more important, since GPR126 activation increases intracellular cAMP levels. As a consequence, intracellular cAMP upregulation leads to PKA and Oct6 activation, which in turn initiates a transcriptional cascade; Oct6 and Sox10, alongside other factors, promote Krox20-mediated myelination (Monk et al., 2015). The GPR126 Gi coupling is likely involved in fine cAMP tuning during development and, probably, in the indirect modulation of Rac1 through a Gi by subunits mediated mechanism, also involving PI3K (Mogha et al., 2013).

Recent observations suggested that GPR126 may play a role also in the regeneration process following nerve injury (Mogha et al., 2016). In this context, GPR126 was proved to be necessary for the upregulation of several chemokines (e.g., tumor necrosis factor, TNF), and some of them downstream targets, such as Ccl2, Ccl3, and Cxcl10. The role of cAMP modulation on these effects still needs to be elucidated (Mogha et al., 2016).

GPR44 is another GPCR involved in myelin formation and maintenance (Trimarco et al., 2014). A recent study showed that NRG-1 type III upregulates prostaglandin D2 (PD2) synthase, which produces PD2 in turn activating GPR44 (Trimarco et al., 2014). Consequently, GPR44 activation leads to the de-phosphorylation of the nuclear factor of activated T-cells (NFAT) isoform c4 (NFATc4), that controls the expression of Krox20 and P0 (Kao et al., 2009). Importantly, also GPR44 is involved in the modulation of NRG-1 type III signaling in SCs (Trimarco et al., 2014).

**PI3K/Akt/mTOR**

NRG-1/ErbB signaling is the main determinant of SC development. NRG-1/ErbB mediated activation of the PI3K pathway leads to the phosphorylation of 3-phosphoinositide dependent protein kinase-1 (PKD1), which in turn converts phosphatidylinositol diphosphate (PIP2) to phosphatidylinositol triphosphate (PIP3), then activating Akt. Different studies supported the importance of this pathway in SC development (Maurel and Salzer, 2000; Ogata et al., 2006). However, NRG1 has a role also in myelination control (Taveggia, 2016).
Ablation of the phosphatase and tensin homolog (PTEN), a lipid phosphatase whose effects are opposite to PDK1, was reported to induce increased SC wrapping and axon hypermyelination (Goebbels et al., 2010). These effects were ameliorated by the mTOR inhibitor rapamycin, demonstrating they were due to Akt-mediated mTOR activation (Goebbels et al., 2012). Prenatal inactivation of mTOR in SCs impaired myelination, supporting the hypothesis of its role in the myelination process (Sherman et al., 2012). Interestingly, the mTOR-mediated control of peripheral myelination seems to be due to mTORC1. Indeed, only the selective ablation of Raptor, a specific mTORC1 adaptor, led to impaired myelination and abnormal cell sorting, whereas the ablation of the mTORC2 adaptor Rictor had no effect (Norrmén et al., 2014). Another hypothesis dealing with the role of mTOR in myelination is based on the relevance of the Raptor-mediated control of the sterol regulatory element-binding protein 1 (SREBP-1) expression, which affects lipid metabolism independently from ErbB signaling (Norrmén et al., 2014).

Overall, the fine mechanism carried out by mTOR during myelination is not completely clear, although mTOR is broadly considered a key regulator of protein translation in the PNS (Laplante and Sabatini, 2013).

**Mitogen-Activated Protein Kinase (MAPK), Erk and p38**

Both MAPK, Erk1/2 and p38, were shown to be fundamental in the control of SC differentiation, although their action is partially contradictory. Indeed, they were proved to act either as positive or negative regulators of myelination.

Some evidence suggested that MAPK is an intracellular pathway downstream NRG-1/ErbB, mediating some effects on myelination. Erk1/2 ablation during development was shown to impair SC differentiation and myelination (Newbern et al., 2011). In agreement, the activation of the Erk1/2 pathway led to increased myelin growth (Ishii et al., 2013; Sheean et al., 2014). In particular, the constitutive activation of the Erk pathways could replace NRG-1/Erb signaling in myelination (Sheean et al., 2014), even when other pathways downstream NRG-1 control, such as phosphor-lipase C-γ (PLCγ) and PI3K-Akt-mTOR, were not activated. Accordingly, the phosphatase Shp2, which activates the Erk1/2 signaling pathway, was shown to be necessary for SC differentiation and myelination, since its conditional knockout led to a phenotype overlapping the ErbB2 knockout mice (Grossmann et al., 2009). Deletion of the scaffolding protein Gab1 reduced Erk activation, resulting in hypomyelination (Shin et al., 2014). In addition, Erk pathway may activate also the pro-myelinating transcriptional factor YY1 (He et al., 2010).

Also the p38 MAPK signaling pathway seems to play a pro-myelinating role at the early stages of myelination, since its inhibition at the time when myelination strats, was reported to block myelin formation (Fragoso et al., 2003).

In contrast, different studies suggested that the activation of MAPK pathways might lead to the negative regulation of myelination and to the induction of the SC repairing phenotype. Indeed, the inhibition of Erk1/2 and p38 MAPK pathways was shown to enhance cell myelination in culture, while p38 activation blocks the cAMP-mediated myelin gene expression and SC differentiation (Syed et al., 2010; Yang et al., 2012). In vivo, Erk1/2 were rapidly activated in the distal stump after nerve injury (Harrisingh et al., 2004; Guertin et al., 2005), and their inhibition blocked SC de-differentiation from the myelinating toward the repairing SC phenotype (Harrisingh et al., 2004; Napoli et al., 2012). Importantly, Raf-1 mediated Erk1/2 activation led to SC de-differentiation and de-myelination, even in the absence of nerve injury (Napoli et al., 2012). The signal initiating Erk1/2 activation after injury is not clear, although some evidence suggested that it could be ErbB2. This hypothesis is based on the observation that its blockade produced effects similar to Erk1/2 deletion, such as myelin breakdown and SC proliferation (Guertin et al., 2005; Napoli et al., 2012; Kim et al., 2013). In addition, p38 MAPK plays similar roles after nerve injury. Its inhibition, indeed, was shown to lessen in vivo de-myelination after nerve injury as well as in vitro SC de-differentiation (Yang et al., 2012).

In conclusion, it is evident that MAPK activation in SCs may act under different circumstances, as positive or negative regulator of myelination. MAPK seems to play a pro-myelinating role during development and an anti-myelinating role after nerve injury. This dualistic role may depend on the lasting of activation. Indeed, transient activation during developmental stages may be linked to positive myelination modulation, while long-term activation following nerve injury may lead to its negative modulation (Glenn and Talbot, 2013; Kim et al., 2013).

**PLCγ-NFAT**

The PLCγ-NFAT pathway was suggested to be important for SCs, in particular for the modulation of gene expression during SC myelination and maturation. NRG-1 binding to ErbB2/ErbB3 receptor complex activates also PLCγ, leading to increased intracellular Ca²⁺ levels and activation of the protein phosphatase calcineurin B. This phosphatase is responsible for cytosolic NFAT dephosphorylation, specifically for what regards NFATc3 and c4 (Kao et al., 2009). ErbB inhibitors proved able to block such an effect, whereas PI3K and MAPK inhibitors did not influence it, suggesting that these two pathways are not involved in the modulation of NFAT dephosphorylation.

NFAT proteins may accumulate in the nucleus, where NFATc4 synergistically co-activates, alongside Sox10, the myelin-specific enhancer (MSE) region of Krox20, inducing its expression (Kao et al., 2009). This mechanism of control is likely dependent on increased intracellular cAMP levels, necessary for NFAT nuclear translocation (Kipanyula et al., 2013). Moreover, NFATc4 and Sox10 exert also a synergic control of P0 promoter, regulating myelination (Kao et al., 2009). Hereafter, given that P0 is also dependent by Krox20, these observations mean that NFAT regulate P0 expression directly and indirectly (Kao et al., 2009).
Neuroactive Steroids/GABA Receptors

Neuroactive steroids, including progestagens, are hormones active and synthesized in the nervous system. The progesterone metabolite 5α-pregnan-3α-ol-20-one, named tetrahydroprogesterone or ALLO, is the most important neuroactive steroid (Baulieu and Robel, 1990), targeting both neurons and glial cells in the central nervous system and in the PNS. In particular, the PNS is a target of neuroactive steroids, since it expresses the common progestagen receptors, such as the classic progesterone receptor (PR) and the non-classic GABA-A receptor (Faroni and Magnaghi, 2011). It is well established that ALLO may act through the GABA-A receptor, modulating Cl-ion flux and exerting non-genomic actions (Puia et al., 1990, 2015), albeit alternative mechanisms have been recently hypothesized (Cooke et al., 2013; Pang et al., 2013). SCs synthesize ALLO and simultaneously may be a target of its actions (Faroni and Magnaghi, 2011).

In the PNS, ALLO participates in the control of myelination, nerve regeneration and likely nociception (Magnaghi et al., 2006, 2010; Faroni and Magnaghi, 2011; Melfi et al., 2017).

It was mentioned (see above) that, in SCs, Src is directly activated by ALLO through a GABA-A dependent mechanism, involving the modulation of FAK (Melfi et al., 2017). This determines remodeling and proliferation of SCs, associated to a promotion of in vitro myelination and increase in the internodes distance (Figure 2C) (Melfi et al., 2017).

Interestingly, several proofs collected in the last decade demonstrated that also the GABA-B receptor is relevant in the control of SC development, maturation and plasticity (Procacci et al., 2012; Faroni et al., 2014; Magnaghi et al., 2014; Corell et al., 2015). Hitherto, it was not established whether the GABA-B receptor in the PNS, in particular in SCs, might be a direct target of neuroactive steroids, such as ALLO. Interestingly, the cross-regulation between GABA-A and GABA-B receptors in SCs was partially characterized (Magnaghi et al., 2006), representing an alternative mechanism of SC regulation that needs further investigation.

C-Jun

Recently, the transcription factor c-Jun was shown to be the key modulator of SC plasticity towards the repairing phenotype.

As a matter of fact, c-Jun expression changes during SC development. Its expression is low or absent in SC precursors, but later it is upregulated in immature SCs, via Krox20-mediated mechanism (Jessen and Mirsky, 2016). In mature SCs, c-Jun is strongly downregulated, although it is still detectable in non-myelinating and (to a lesser extent) in myelinating SCs (Jessen and Mirsky, 2016). Meanwhile c-Jun is a negative modulator of SC myelination, suppressing som myelin genes including Krox20, P0 and MBP (Parkinson et al., 2004, 2008).

Importantly, c-Jun is rapidly upregulated in injured nerves. In fact studies performed in SCs obtained from conditional knockout mice proved that c-Jun is not essential during development, but it is required for functional regeneration and post-injury axonal recovery (Arthur-Farraj et al., 2012). After nerve injury, c-Jun mediates the de-differentiation from the SC myelinating phenotype, as well as the subsequent activation of the repairing program in PNS. c-Jun was shown to be necessary for the upregulation of important factors involved in axonal growth and survival, such as GDNF, BDNF, p75-NTR and N-cadherin. In particular, GDNF and N-cadherin are directly targeted by c-Jun (Arthur-Farraj et al., 2012; Fontana et al., 2012).

Interestingly, c-Jun seems to play a role in the so called myelinophagy process, which is a specialized mTOR-independent autophagy process by which SCs start to remove...
myelin following nerve damage (Jessen and Mirsky, 2016). c-Jun also participates in the macrophage recruitment after nerve injury (Arthur-Farraj et al., 2012).

**Mechanical Cues**

Mechanobiology is a field of science studying the effect of physical forces, such as stretching and compression, on living systems (Halder et al., 2012). By activating mechanotransduction systems, cells translate the physical stimuli into biochemical signals, controlling multiple aspects of cell behavior, including growth, differentiation and tumor progression (Dupont et al., 2011). For instance, physical properties of the extracellular matrix and mechanical forces are integral to morphogenetic processes in embryonic development, defining tissue architecture (Mammoto and Ingber, 2010; Dupont et al., 2011). For a long time, the biology of dysmyelination and demyelination have been studied under myelin pathological conditions, although the study of mechanical stimuli that guide the development of myelinating glial cells was only recently addressed (Jagielska et al., 2012; Lourenço et al., 2016). SCs were shown to be mechanosensitive, albeit the nature of forces that affect their differentiation in vivo remains to be fully established, as well as the potential implication of these pathogenic alterations in tumorigenesis (Poitelon et al., 2017).

In this context, the Hippo pathway (see above) has been described as one of the most important effector of SC changes following physical challenges. YAP and TAZ proved to be activated by mechanical stimuli, in turn regulating SC proliferation and transcription of basal lamina receptor genes (Poitelon et al., 2016). Recently, the exposure to electromagnetic fields has been indicated as an environmental challenge affecting SCs development (Lacy-Hulbert et al., 1998; Colciago et al., 2015). The electromagnetic field exposure induces YAP dysregulation, changing its intracellular localization; these effects were associated with increased SC proliferation and decreased differentiation. In normal cells YAP is mainly localized in the nucleus, where it controls proliferation and apoptosis, while in SCs exposed to electromagnetic field YAP is mostly present in the cytoplasm (Colciago et al., 2015), likely losing its tumor suppressor capability (Figure 3).

Taken together, these findings suggest mechanobiology as an emerging and promising field of study in SC biology, even its relevance and importance in the pathophysiology of SCs needs further studies.

**Conclusions**

SCs are the main glial cells in the PNS, involved in several hereditary, metabolic and traumatic diseases. In the last thirty years, a huge amount of data in the scientific literature pointed out the role of growth factors, neuregulins, integrins, hormones and neurotransmitters in SC regulation, under different pathophysiological conditions. In this review, we presented some of the more recent findings on novel signaling pathways that proved important in regulating the different stages of SCs, from development to maturation, myelination, plasticity and nerve repair.

The analysis of the different signaling pathways involved in SC regulation suggests the existence of a complex integrated system, responsible for the remarkable plasticity exhibited by SCs. A better understanding of these processes will foster the understanding of the basic mechanisms and the identification of possible reliable therapies for the PNS pathologies. Indeed, peripheral neuropathies are well known to cause significant morbidity and decreased quality of life. In particular, SCs are a promising target for the treatment of acquired conditions, such as traumatic damage of peripheral nerves (Faroni et al., 2015), and genetic diseases, such as different forms of Charcot-Marie-Tooth disease (Mathis et al., 2015). Different strategies (see the review by Zhou and Notterpek, 2016) have been recently proposed to treat demyelinating pathologies, some of which (e.g., ascorbic acid or progesterone antagonists) resulted in unreliable outcomes for clinical practice. Although other actions or therapeutic strategies, such as caloric restriction (likely involving the PI3K/Akt/mTOR signaling) or exercise may reverse the myelin damage and promote the nerve regeneration, little is known about the specific pathways on which these proposed new therapies act in SCs, making further studies necessary.

**References**

Arthur-Farraj PJ, Latouche M, Wilton DK, Quintes S, Chabrol E, Baumerjee A, Woodhoo A, Jenkins B, Rahman M, Turmaine M, Wichser GK, Mitter R, Greensmith L, Behrens A, Raivich G, Mirsky R, Jessen KR (2012) c-Jun reprograms schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron 75:633-647.

Bare DJ, Lauder JM, Wilkie MB, Maness PF (1993) p59fyn in rat brain neurons and glia. Oncogene 8:1429-1436.

Benninger Y, Thurnherr T, Pereira JA, Krause S, Wu X, Chrostek-Grashoff A, Herzog D, Nave KA, Franklin RJM, Meijer D, Brakebusch C, Suter U, Relvas JB (2007) Essential and distinct roles for cdc42 and rac1 in the regulation of Schwann cell biology during peripheral nervous system development. J Cell Biol 177:1051-1061.

Bordinaro M, Lazarova DI, Sartorell AC (2007) The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res 313:1652-1666.

Baulieu EE, Robel P (1990) Neurosteroids: a new brain function? J Steroid Biochem Mol Biol 37:395-403.

Benninger Y, Thurnherr T, Pereira JA, Krause S, Wu X, Chrostek-Grashoff A, Herzog D, Nave KA, Franklin RJM, Meijer D, Brakebusch C, Suter U, Relvas JB (2007) Essential and distinct roles for cdc42 and rac1 in the regulation of Schwann cell biology during peripheral nervous system development. J Cell Biol 177:1051-1061.
Grossmann KS, Wende H, Paul FE, Cheret C, Garratt AN, Zurborg S, Feinberg K, Beisser D, Schulz H, Peles E, Selbach M, Birchmeier W, Birchmeier C (2009) The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-1/Erbb signaling throughout Schwann cell development. Proc Natl Acad Sci U S A 106:16704-16709.

Grove M, Brophy PJ (2014) FAK is required for schwann cell spreading on immature basal lamina to coordinate the radial sorting of peripheral axons with myelination. J Neurosci 34:13422-13434.

Grove M, Kim H, Santerre M, Krupka AJ, Han SB, Zhai J, Cho JY, Park R, Harris M, Kim S, Sawaya BE, Kang SH, Barbe MF, Cho SH, Lemay MA, Son YJ (2017) YAP/TAZ initiate and maintain Schwann cell myelination. Elife 6:e20982.

Grove M, Komiyama NH, Nave KA, Grant SG, Sherman DL, Brophy PJ (2007) FAK is required for axonal sorting by Schwann cells. J Cell Biol 176:277-282.

Guertin AD, Zhang DP, Mak KS, Alberta JA, Kim HA (2005) Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci 25:3478-3487.

Guo L, Lee AA, Rizvi TA, Ratner N, Kirschner LS (2013a) The protein kinase A regulatory subunit 1B1 (Prkar1a) plays critical roles in peripheral nerve development. J Neurosci 33:17967-17975.

Guo L, Moon C, Niehaus K, Zheng YY, Ratner N (2012) Rac1 controls schwann cell myelination through AMP and NF2/merlin. J Neurosci 32:17251-17261.

Guo L, Moon C, Zheng Y, Ratner N (2013b) Cdc42 regulates Schwann cell radial sorting and myelin sheath folding through NF2/merlin-dependent and independent signaling. Glia 61:1906-1921.

Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT, Rutherford SA, Trump D, Newman WG, Evans DG (2010) Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216-6221.

Halder G, Dupont S, Piccolo S (2012) Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol 13:391-401.

Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC (2004) The Ras/Raf/ERK signaling pathway drives Schwann cell dedifferentiation. EMBO J 23:3061-3071.

He Y, Kim JY, Dupree J, Tewari M, Melendez-Vasquez C, Svanen J, Cassacca P (2010) Yyl as a molecular link between neuregin and transcriptional modulation of peripheral myelination. Nat Neurosci 13:1472-1480.

Hirokawa Y, Tiko A, Huyhn J, Utermark T, Hanemann CO, Giovannini M, Xiao GH, Testa JR, Wood J, Maruta H (2004) A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer 10:20-26.

Iishi A, Furusho M, Bansal R (2013) Sustained activation of EKRK1/2 MAPK in oligodendrocytes and schwann cells enhances myelin growth and stimulates oligodendrocyte progenitor expansion. J Neurosci 33:175-186.

Jacob C, Christen CN, Pereira JA, Somandini C, Baggiolini A, Lötzerich P, Özçelik M, Tricaud N, Meijer D, Yamaguchi T, Matthias P, Suter U (2011) HDAC1 and HDAC2 control the transcriptional program of myelination and the survival of Schwann cells. Nat Neurosci 14:429-436.

Jacob C, Lötzerich P, Engler S, Baggiolini A, Varuni Tavares S, Brügger V, John N, Bückmann-Moller S, Snider PL, Conway SJ, Yamaguchi T, Matthias P, Sommer L, Mantei N, Suter U (2014) HDAC1 and HDAC2 control the specification of neural crest cells into peripheral glia. J Neurosci 34:6112-6122.

Jagielska A, Norman AL, Whyte G, Vlet KJ Van, Guck J, Franklin RJ (2012) Mechanical environment modulates biological properties of oligodendrocyte progenitor cells. Stem Cells Dev 21:2905-2914.

Jessen KR, Mirska R (2005) The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci 6:671-682.

Jessen KR, Mirska R (2016) The repair Schwann cell and its function in regenerating nerves. J Physiol 594:1521-1531.

Kao SC, Wu H, Xie J, Chang CP, Ranish JA, Graef IA, Crabtree GR (2009) Calcineurin/NFAT signaling is required for neuregulin-regulated Schwann cell differentiation. Science 323:651-654.
Kim M, Kim T, Johnson RL, Lim DS (2015) Transcriptional co-regres-
sor function of the hippo pathway transducers YAP and TAZ. Cell
Rep 11:270-282.
Kipanjiya MJ, Woodhoo A, Rahman M, Payne D, Jessen KR, Mrsky
R (2013) Calcineurin-nuclear factor of activated t cells regulation
of Krox-20 expression in Schwann cells requires elevation of intracellu-
lar cyclic AMP. J Neurosci Res 91:105-115.
Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T (2003)
Meroni, the product of the p21 tumor suppressor gene, is an inhibi-
tor of the p21-activated kinase, Pak1. Mol Cell 12:841-849.
Lacy-Hulbert A, Metcalfe JC, Hesketh R (1998) Biological responses
to electromagnetic fields. FASEB J 12:392-402.
Laplante M, Sabatini DM (2013) Regulation of mTORC1 and its
impact on gene expression at a glance. J Cell Sci 126:1713-1719.
Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zaggz D,
Snudler M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA,
Giancotti FG (2014) Merlin/NF2 loss-of-function tumorigenesis linked
to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinetics
Late2 and 1 in the nucleus. Cancer Cell 26:48-60.
Li W, Giancotti FG (2010) Merlin’s tumour suppression linked to inhibi-
tion of the E3 ubiquitin ligase CRL4 (DCAF1). Cell Cycle 9:4433-4436.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
lopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Oncotarget 8:5680-5681.
Lopez-Anido C, Poitelon Y, Gopinath C, Moran JJ, Ma KH, Law WD,
Puia G, Ravazzini F, Castelnovo LF, Magnaghi V (2015) PKCε and al-
llopregnanolone: functional cross-talk at the GABAA receptor level.
Quintes S, Brinkmann BG, Ebert M, Fröh F, Kungl T, Arlt FA, Tarabyskin V, Huylebroeck D, Meijer D, Suter U, Wegner M, Sereda MW, Nave KA (2016) Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair. Nat Neurosci 19:1050-1059.

Raphael AR, Talbot WS (2011) New insights into signaling during myelination in zebrafish. Curr Top Dev Biol 97:1-19.

Salzer JL (2015) Schwann cell myelination. Cold Spring Harb Perspect Biol 7:a02529.

Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 14:1680-1688.

Schwartz MA, Shattil SJ (2000) Signaling networks linking integrins and rho family GTPases. Trends Biochem Sci 25:388-391.

Sheah NM, Marchionni MA, Isaacs I, Stroobant P, Anderson DJ (1994) Glial growth factor restricts mammalian neural stem cells to a glial fate. Cell 77:349-360.

Sheean MC, McShane E, Cheret C, Walcher J, Müller T, Wulff-Goldenberg A, Hoelper S, Garratt AN, Krüger M, Rajewsky K, Meijer D, Birchmeier W, Lewin GR, Selbach M, Birchmeier C (2014) Activation of MAPK overrides the termination of myelin growth and replaces Ngr1/Erbb3 signals during Schwann cell development and myelination. Genes Dev 28:290-303.

Sherman DL, Krols M, Wu LM, Grove M, Nave KA, Gangloff YG, Brophy PJ (2012) Arrest of myelination and reduced axon growth when Schwann cells lack mTOR. J Neurosci 32:1817-1825.

Shin YK, Jang SY, Park SY, Park JY, Kim JKP, Kim JKP, Suh DJ, Lee HJ, Park HT (2014) Grb2-associated binder-1 is required for neuregulin-1-induced peripheral nerve myelination. J Neurosci 34:7657-7662.

Stuhlmüller TJ, García-Castro MI (2012) Current perspectives of the signaling pathways directing neural crest induction. Cell Mol Life Sci 69:3715-3737.

Svaren J (2008) MicroRNA and transcriptional crosstalk in myelinating glial cells. Trends Neurosci 31:300-307.

Svaren J (2014) MicroRNA and transcriptional crosstalk in myelinating glial cells. Trends Neurosci 37:300-307.

Syed N, Reddy K, Yang D, Taveggia C, Salzer JL, Maurel P, Kim HA (2010) Soluble neuregulin-1 has bi-functional, concentration-dependent effects on Schwann cell myelination. J Neurosci 30:6122-6131.

Taveggia C (2016) Schwann cells–axon interaction in myelination. Curr Opin Neurobiol 39:24-29.

Terashima T, Yasuda H, Terada M, Kogawa S, Maeda K, Haneda M, Kashihwagi A, Kikkawa R (2001) Expression of Rho-family GTPases (Rac, cdc42, RhoA) and their association with p-21 activated kinase (Rac, cdc42, RhoA) and their association with p-21 activated kinase. J Neurochem 77:996-999.

Thaxton C, Bott M, Walker B, Sparrow NA, Lambert S, Fernandez-Valle C (2011) Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length. Mol Cell Neurosci 47:1-9.

Thaxton C, Lopera J, Bott M, Fernandez-Valle C (2008) Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 27:2705-2715.

Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi A, Bainsoudou T, Barret C, Chauray P (1994) Krox-20 controls myelination in the peripheral nervous system. Nature 371:796-799.

Torres-Martín M, Lasaletta L, de Campos JM, Isla A, Gavilan J, Pinto GR, Burbano RR, Latif F, Meléndez B, Casaresana J, Rey J (2013) Global profiling in vestibular schwannomas shows critical deregulation of MicroRNAs and upregulation in those included in chromosomal region 1q32 Galardy PJ, ed. PLoS One 8:e65886.

Trimarco A, Force MG, Aliferi V, Lucente A, Brambilla P, Dina G, Pieragostino D, Sachetta P, Urade Y, Boizet-Bonhoure B, Boneschi FM, Quattrarini A, Taveggia C (2014) Prostaglandin D2 synthase/ GPR44: a signaling axis in PNS myelination. Nat Neurosci 17:1682-1692.

Woodhoo A, Alonso MBA, Droghetti A, Turmaine M, D’Antonio M, Parkinson DB, Wilton DK, Al-Shawi R, Simons P, Shen J, Guillemt F, Radtke F, Meijer D, Felti ML, Wraithet L, Mirsky R, Jessen KR (2009) Notch controls embryonic Schwann cell differentiation, postnatal myelination and adult plasticity. Nat Neurosci 12:839-847.

Woodhoo A, Sommer L (2008) Development of the Schwann cell lineage from the neural crest to the myelinated nerve. Glia 56:1481-1490.

Xing Z, Chen HC, Nowlen JK, Taylor S, Shalloway D, Guan JL (1994) Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell 5:413-421.

Yang DP, Kim J, Syed N, Tung YJ, Bhaskaran A, Mindos T, Mirsky R, Jessen KR, Maurel P, Parkinson DB, Kim HA (2012) p38 MAPK activation promotes differentiated Schwann cell phenotype and functions as a negative regulator of Schwann cell differentiation and myelination. J Neurosci 32:7158-7168.

Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan K (2009) TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 284:33355-33362.

Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19:27-38.

Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962-1971.

Zhao YL, Takagawa K, Oya T, Yang HF, Gao ZY, Kawaguchi M, Ishii Y, Sasaoka T, Owada K, Furuta I, Sasahara M (2003) Active Src expression is induced after rat peripheral nerve injury. Glia 42:184-193.

Zhou Y, Notterpek L (2016) Promoting peripheral myelin repair. Exp Neurol 283:573-580.